Overview
Short and Optimal Duration of Dual Antiplatelet Therapy Study
Status:
Completed
Completed
Trial end date:
2014-12-01
2014-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate safety of reduction of thienopyridine treatment period to 3 months after implantation of Cobalt-Chromium everolimus-eluting Stents.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Takeshi Morimoto
Criteria
Inclusion Criteria:- Patients who received PCI using everolimus-eluting cobalt-chromium stents
Exclusion Criteria:
- Patients who had been implanted drug-eluting stents other than everolimus-eluting
cobalt-chromium stents